Glenmark Pharmaceuticals, a drug firm said it has received final approval for Abiraterone Acetate tablets from the US health regulator. These tablets are used in treatment of prostate cancer. The approved product is a generic version of Zytiga tablets, 250 mg, of Janssen Biotech.
According to the company in its regulatory filing, “Glenmark Pharmaceuticals Inc., USA has been granted final approval by the United States Food & Drug Administration (USFDA) for Abiraterone Acetate tablets USP, 250 mg.”
As per the sales data by IQVIA for the 12-month period that ended in August 2019, Glenmark said that the Zytiga tablets, 250 mg market has achieved an annual sale of approximately US$ 794.1 million.
Currently, Glenmark’s portfolio has 162 products authorised for distribution in the US marketplace and 46 ANDA’s pending approval with the USFDA.
Source: IBEF
Image Courtesy: IndiaMart
You may also like
-
Wockhardt’s Zaynich Opens a New Chapter for Indian Antibiotic Innovation
-
Cinnamon in Ayurveda: The Sweet Heat That Awakens Digestion and Circulation
-
Gingelly / Sesame in Ayurveda: The Tiny Seed That Became Food, Oil and Medicine
-
Tamarind in Ayurveda: The Sour Fruit That Turned Indian Food Into Medicine
-
Ayushman Bharat Digital Mission Crosses 90 Crore ABHA Accounts, Strengthening India’s Digital Health Backbone
